Table 5 Performance of Simprova-RV compared with the reference rPCR and RADT in a prospective clinical study.
Target | No. of positive specimens tested by rPCR | Simprova-RVa | RADTa | |
|---|---|---|---|---|
IAV | 50 | Sensitivity % | 90.0% (78.2–96.7%) | 58.0% (43.2–71.8%) |
Specificity % | 100% (98.9–100%) | 100% (98.9–100%) | ||
PPV % | 100% | 100% | ||
NPV % | 98.5% (96.6–99.3%) | 94.0% (91.9–95.6%) | ||
IBV | 11 | Sensitivity % | 90.9% (58.7–99.8%) | 36.4% (10.9–69.2%) |
Specificity % | 100% (99.0–100%) | 100% (99.0–100%) | ||
PPV % | 100% | 100% | ||
NPV % | 99.7% (98.3–100%) | 98.1% (97.1–98.8%) | ||
RSV | 108 | Sensitivity % | 84.3% (76.0–90.6%) | 56.5% (46.6–66.0%) |
Specificity % | 100% (98.7–100%) | 100% (98.7–100%) | ||
PPV % | 100% | 100% | ||
NPV % | 94.1 (91.2–96.1%) | 85.3% (82.4–87.8%) | ||
hMPV | 61 | Sensitivity % | 73.8% (60.9–84.2%) | 65.6% (52.3–77.3%) |
Specificity % | 100% (98.9–100%) | 100% (98.9–100%) | ||
PPV % | 100% | 100% | ||
NPV % | 95.2% (92.9–96.8%) | 93.8% (91.5–95.6%) |
